Tag: Teva
Teva back on the hook for $235M to GSK for heart...
After a jury in 2017 ordered Teva to pay $235 million for patent infringement of a GlaxoSmithKline heart drug, the generics giant convinced a district...
Gilead’s Truvada faces Teva generics assault amid Descovy switching campaign
When its U.S. patent cliff for HIV med Truvada was still on the horizon, Gilead Sciences won approval for follow-up med Descovy and launched an...
Teva CEO Schultz took a big pay cut last year—but he...
Teva has undergone a massive transformation in the past two years after a $3 billion restructuring fundamentally reshaped the Israeli drugmaker's operations. The man...
‘Boring is good,’ Teva CEO Schultz says amid push to hit...
Teva’s CEO Kåre Schultz had his hands full when he joined the company back in 2017, and while the drugmaker still faces significant challenges, he's...
Teva CEO says manufacturing cuts will keep coming even after $3B...
The way Teva Pharmaceutical CEO Kåre Schultz figures it, manufacturing is the cost-cutting gift that just keeps on giving. After the Israeli drugmaker completes...
Teva, denying ‘any liability,’ set aside $646M for opioid settlements. Here’s...
When Teva reported first-quarter results in April, CEO Kåre Schultz said the company wouldn’t pony up any big settlements because it has a lot of debt...
Teva, amid massive restructuring, closes in on $3B cost-cutting goal
When Kåre Schultz joined Teva as CEO back in November 2017, the drugmaker was in a world of hurt. It was saddled with debt,...
Teva CEO Kåre Schultz nabs whopping $33M in first full year...
If you thought Teva had gone big-time with its 2017 pay package for CEO Kåre Schultz, check out what it paid him in 2018.
The...
Teva forecasts worse-than-expected ‘trough year’ as generics hammer MS drug Copaxone
Shares of Teva fell nearly 12% in pre-market trading to $16.80 after the company’s executives conceded during the fourth-quarter earnings report that 2019 would...
